Upstream Bio, Inc. Common Stock (UPB) Stock
NASDAQ · UPB
Key stats
- Market cap
- $175.40M
- Price / Earnings ratio
- -1.2x
- EPS (TTM)
- -$2.89
- Volume
- Loading
- 52-week high
- $33.68
- 52-week low
- $2.68
Source: third-party data provider, as of November 13, 2026
Compare with UPB
Recent news

Zacks Investment Research
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
UPBAugust 11, 2026
Zacks Investment Research
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
UPB

Zacks Investment Research
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
UPBJuly 14, 2026
Zacks Investment Research
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
UPB

Business Wire
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
UPBJune 12, 2026
Business Wire
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
UPB

Zacks Investment Research
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
UPBMay 13, 2026
Zacks Investment Research
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
UPB
Technical indicators
- RSI 14
- 41.39
- MACD 12/26/9
- -0.27
- EMA 9 of MACD
- -0.39
- MACD histogram
- 0.12
- SMA 50
- $4.38
- Price below SMA 50
- EMA 50
- $4.27
- Price below EMA 50
- SMA 200
- $8.16
- Price below SMA 200
- EMA 200
- $10.26
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Strong Sell0
Sell0
Hold1
Buy1
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2022
2023
2024
2025
3M2M1M0
Debt & Balance Sheet
Total assets
Total liabilities
2022
2023
2024
2025
578M382M191M0
Revenue to Profit
2025$2.9M
Revenue$0.0
Cost of revenue$2.9M
Gross profit$0.0
Operating expenses$-143.4M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
UPBAugust 11, 2026
Zacks Investment Research
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
UPB

Zacks Investment Research
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
UPBJuly 14, 2026
Zacks Investment Research
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
UPB

Business Wire
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
UPBJune 12, 2026
Business Wire
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
UPB

Zacks Investment Research
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
UPBMay 13, 2026
Zacks Investment Research
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
UPB

Investors Business Daily
Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong Dose
UPBFebruary 11, 2026
Investors Business Daily
Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong Dose
UPB
About Upstream Bio, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees75
CEODr. E. Rand Sutherland M.D., M.P.H.
IPO DateOct 11, 2024
HeadquartersWaltham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. E. Rand Sutherland M.D., M.P.H. | CEO & Director | 1970 |
| Mr. Michael Paul Gray CPA, MBA | CFO & COO | 1971 |
| Mr. Aaron Deykin M.D. | Chief Medical Officer and Head of Research & Development | 1967 |
| Ms. Stacy Price M.S., P.M.P. | Chief Technology Officer | 1969 |
| Meggan Buckwell | Director of Corporate Communications & Investor Relations | — |
| Ms. Allison C. Ambrose J.D. | Senior VP, General Counsel & Secretary | 1985 |
| Ms. Lisa Fiering | Senior Vice President of People & Culture | — |
| Dr. Adam Houghton M.B.A., Ph.D. | Chief Business Officer | 1971 |
| Ms. Mersedeh Miraliakbari Pharm.D. | Senior Vice President of Regulatory Affairs & Quality | — |
| Ms. Fang Xie Ph.D. | VP & Head of Biometrics | — |
Fundamentals
Valuation
Price-to-sales ratio66.13
Price-to-book value0.68
Profitability
Return on Equity-48.00%
Return on Assets-47.00%
Return on Sales-4956.00%
Gross margin (latest quarter)100.00%
EBITDA$-155.70M
Trading
Average volume1,268,736
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 41.39
- MACD 12/26/9
- -0.27
- EMA 9 of MACD
- -0.39
- MACD histogram
- 0.12
- SMA 50
- $4.38
- Price below SMA 50
- EMA 50
- $4.27
- Price below EMA 50
- SMA 200
- $8.16
- Price below SMA 200
- EMA 200
- $10.26
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Hold
50% Buy
50% Hold
0% Sell
Analyst price target
- Low
- $9.00
- Average
- $13.50
- High
- $18.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +12.7 | -11.7 | -24.0 | |||||||||
| 2025 | -33.9 | -20.1 | -18.0 | +38.2 | +2.6 | +3.0 | +41.9 | +10.2 | -7.2 | +38.8 | +14.3 | -6.3 |
| 2026 | +14.8 | -74.3 | +16.9 | -1.4 | -11.1 | -14.4 | -13.3 | +3.1 | -19.5 | -32.3 | +0.9 |
Compare stocks
Market cap
$175.40M
-
-
-
Price / Earnings ratio
-1.20
-
-
-
Price / Sales ratio
66.13
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,268,736
-
-
-
Earnings per share
$-2.89
-
-
-



